Chemomab Therapeutics Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Chemomab Therapeutics Ltd. (CMMB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 105.20% for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-03-23
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 84.31%, a 18.95% increase from fiscal 2021.
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 70.88%, a 5.16% increase from fiscal 2020.
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2020 was 67.40%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|
| 2025-12-31 | 105.20% 20-F · filed 2026-03-23 |
| 2024-12-31 | 92.98% 20-F · filed 2025-04-04 |
| 2023-12-31 | 112.94% 20-F · filed 2024-03-28 |
| 2022-12-31 | 84.31% 10-K · filed 2023-03-20 |
| 2021-12-31 | 70.88% 10-K · filed 2022-03-30 |
| 2020-12-31 | 67.40% 10-K · filed 2021-03-09 |